Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGend Therapeutics CoROCO:6733 -2.50%73 Days Payable is 11.69 as of Dec. 2025, which is 78% below its 10-year median of 54.10. GuruFocus rates ROCO:6733 with a GF Score™ of 73/100 and a GF Value™ of NT$70.22 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 701 Biotechnology companies, BioGend Therapeutics Co ranks worse than 92.15% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6733 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, BioGend Therapeutics Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGend Therapeutics Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's Days Payable distribution charts can be found below:
* The bar in red indicates where BioGend Therapeutics Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BioGend Therapeutics Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGend Therapeutics Co (ROCO:6733) has a Days Payable of 11.69 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioGend Therapeutics Co and its competitors. This is 78% below median its historical median of 54.10. Over the past decade, BioGend Therapeutics Co's Days Payable has ranged from 15.37 to 668.80. According to the industry distribution chart, BioGend Therapeutics Co ranks #646 out of 701 companies in the Biotechnology industry, placing it in the top 92.2%.
Is BioGend Therapeutics Co's Days Payable too high?
BioGend Therapeutics Co's current Days Payable of 11.69 is 78% below median its 10-year median of 54.10. Over the past 10 years, this metric has ranged from a low of 15.37 to a high of 668.80. The Biotechnology industry median Days Payable is 112.84. BioGend Therapeutics Co's value of 11.69 is 89.6% below this industry median. Based on the distribution chart, BioGend Therapeutics Co ranks #646 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioGend Therapeutics Co ranks #646 out of 701 companies for Days Payable. This places BioGend Therapeutics Co in the lower half of its industry. The industry median Days Payable is 112.84. BioGend Therapeutics Co's value of 11.69 is 89.6% below this benchmark. Historically, BioGend Therapeutics Co's own Days Payable has ranged from 15.37 to 668.80 over the past decade. While the company's 10-year median is 54.10 vs. the industry median of 112.84, BioGend Therapeutics Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGend Therapeutics Co's current Days Payable of 11.69 is 89.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioGend Therapeutics Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGend Therapeutics Co's current Days Payable is 11.69, which is 78% below median its own 10-year median of 54.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$70.22, compared to a current price of NT$25.35 — trading 63.9% below its estimated fair value. The current Days Payable is 11.69, which is 78% below median its 10-year median of 54.10 and 89.6% below the Biotechnology industry median of 112.84. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current Days Payable is 11.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?
Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued.
The current stock price of NT$25.35 is trading 63.9% below its estimated GF Value™ of NT$70.22.
GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6733:
Days Payable: 11.69 (78% below median its 10-year median of 54.10)
GF Value™: NT$70.22 vs. price of NT$25.35 (63.9% below fair value)
Industry Position: 89.6% below the Biotechnology median (#646 of 701)
No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score
Get the complete analysis for ROCO:6733
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6733 has been successfully added to your 
